Concepedia

Simone Steinbild

SS

Statistics

Publications

15

Citations

1.1K

H-Index

13

Active since

2003

Affiliations

University of Freiburg(Current)

Bayer (Germany)

Heidelberg University

Bayer (United States)

University Medical Center Freiburg

Simone Steinbild is an author at University of Freiburg specializing in pharmacology, cancer pharmacology, and oncology.

Publications per year

2003–2020

15

Publications

15

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Clinical Cancer Research · 2012 · 333 citations

, , +17

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Journal of Clinical Oncology · 2008 · 158 citations · Full text

, , +14

Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin

Clemens Unger, B. Häring, Michael Medinger et al. · Clinical Cancer Research · 2007 · 103 citations · Full text

, , +16

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV

Simone Steinbild, K. Mross, Annette Frost et al. · British Journal of Cancer · 2007 · 102 citations · Full text

, , +15

Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib

K. Mross, Simone Steinbild, F. Baas et al. · European Journal of Cancer · 2006 · 101 citations

, , +8

1–5 of 15